<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Canadian Pharmacy Blog &#187; Aripiprazole</title>
	<atom:link href="http://annpharmacy.com/blog/tag/aripiprazole/feed" rel="self" type="application/rss+xml" />
	<link>http://annpharmacy.com/blog</link>
	<description>Health, Diseases, Drugs &#38; medications, Online canadian pharmacy</description>
	<lastBuildDate>Wed, 28 Jul 2010 16:32:20 +0000</lastBuildDate>
	<generator>http://wordpress.org/?v=2.8.1-beta1</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>ABILIFY (Aripiprazole) In Treatment Of Depression Disorder</title>
		<link>http://annpharmacy.com/blog/anti-acidity/abilify-aripiprazole-in-treatment-of-depression-disorder.html</link>
		<comments>http://annpharmacy.com/blog/anti-acidity/abilify-aripiprazole-in-treatment-of-depression-disorder.html#comments</comments>
		<pubDate>Sun, 21 Feb 2010 08:43:33 +0000</pubDate>
		<dc:creator>John Mitchell</dc:creator>
				<category><![CDATA[Anti-Acidity]]></category>
		<category><![CDATA[Anti-Depressants]]></category>
		<category><![CDATA[Abilify]]></category>
		<category><![CDATA[Aripiprazole]]></category>
		<category><![CDATA[bipolar disorder]]></category>
		<category><![CDATA[Depression]]></category>
		<category><![CDATA[Schizophrenia]]></category>

		<guid isPermaLink="false">http://annpharmacy.com/blog/?p=193</guid>
		<description><![CDATA[ABILIFY (Aripiprazole)  drug was developed by two companies: Otsuka Pharmaceutical Co., Ltd and  Bristol-Myers Squibb Company. In 2004 Abilify  medicine was approved in for treating schizophrenia disease and in 2008 it  was ratified as medicine for bipolar  disorder.
It has been known today that the U.S. Food and Drug  Administration (FDA) [...]]]></description>
		<wfw:commentRss>http://annpharmacy.com/blog/anti-acidity/abilify-aripiprazole-in-treatment-of-depression-disorder.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Abilify (Aripiprazole) Medicine For Bipolar Disorder Is Allowed To Be Marketing</title>
		<link>http://annpharmacy.com/blog/anti-acidity/abilify-aripiprazole-medicine-for-bipolar-disorder-is-allowed-to-be-marketing.html</link>
		<comments>http://annpharmacy.com/blog/anti-acidity/abilify-aripiprazole-medicine-for-bipolar-disorder-is-allowed-to-be-marketing.html#comments</comments>
		<pubDate>Mon, 15 Feb 2010 15:33:54 +0000</pubDate>
		<dc:creator>John Mitchell</dc:creator>
				<category><![CDATA[Anti-Acidity]]></category>
		<category><![CDATA[Anti-Depressants]]></category>
		<category><![CDATA[Abilify]]></category>
		<category><![CDATA[Aripiprazole]]></category>
		<category><![CDATA[bipolar disorder]]></category>
		<category><![CDATA[Schizophrenia]]></category>

		<guid isPermaLink="false">http://annpharmacy.com/blog/?p=190</guid>
		<description><![CDATA[Abilify drug was  generally approved in 2004 for treating schizophrenia  disease and this medicine was supposed to be used in treating bipolar disorder. Indeed, on  April 8, 2008, the European Commission allowed Abilify medication (Aripiprazole) to be marketed for patients with Bipolar I Disorder.
Such kind of disease as Bipolar I Disorder contains [...]]]></description>
		<wfw:commentRss>http://annpharmacy.com/blog/anti-acidity/abilify-aripiprazole-medicine-for-bipolar-disorder-is-allowed-to-be-marketing.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Oral Solution Formulation of Abilify (Aripiprazole) Is Ratified</title>
		<link>http://annpharmacy.com/blog/anti-acidity/oral-solution-formulation-of-abilify-aripiprazole-is-ratified.html</link>
		<comments>http://annpharmacy.com/blog/anti-acidity/oral-solution-formulation-of-abilify-aripiprazole-is-ratified.html#comments</comments>
		<pubDate>Tue, 09 Feb 2010 11:21:29 +0000</pubDate>
		<dc:creator>John Mitchell</dc:creator>
				<category><![CDATA[Anti-Acidity]]></category>
		<category><![CDATA[Anti-Depressants]]></category>
		<category><![CDATA[Abilify]]></category>
		<category><![CDATA[Aripiprazole]]></category>
		<category><![CDATA[Schizophrenia]]></category>

		<guid isPermaLink="false">http://annpharmacy.com/blog/?p=187</guid>
		<description><![CDATA[Abilify antipsychotic  medicine was introduced in 2002 as the first and only dopamine partial agonist. It is  generally prescribed for the treatment of schizophrenia  disease and acute manic and mixed episodes associated with bipolar  disorder.
It has been known today that the US Food and Drug  Administration (FDA) approved an oral [...]]]></description>
		<wfw:commentRss>http://annpharmacy.com/blog/anti-acidity/oral-solution-formulation-of-abilify-aripiprazole-is-ratified.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>FDA Granted A Priority Review To Abilify(R) (Aripiprazole) Supplemental New Drug Application</title>
		<link>http://annpharmacy.com/blog/anti-acidity/fda-granted-a-priority-review-to-abilifyr-aripiprazole-supplemental-new-drug-application.html</link>
		<comments>http://annpharmacy.com/blog/anti-acidity/fda-granted-a-priority-review-to-abilifyr-aripiprazole-supplemental-new-drug-application.html#comments</comments>
		<pubDate>Wed, 27 Jan 2010 13:14:48 +0000</pubDate>
		<dc:creator>John Mitchell</dc:creator>
				<category><![CDATA[Anti-Acidity]]></category>
		<category><![CDATA[Anti-Depressants]]></category>
		<category><![CDATA[Abilify]]></category>
		<category><![CDATA[antipsychotic medication]]></category>
		<category><![CDATA[Aripiprazole]]></category>
		<category><![CDATA[Schizophrenia]]></category>

		<guid isPermaLink="false">http://annpharmacy.com/blog/?p=184</guid>
		<description><![CDATA[Abilify  (Aripiprazole) is considered to be an effective antipsychotic medication for treating schizophrenia disease and Bipolar I  Disorder. The drug is developed by two partnered companies: Otsuka  Pharmaceutical Co., Ltd. and Bristol-Myers Squibb Company.
They announced that the U.S. Food and Drug  Administration (FDA) has accepted the supplemental New Drug Application (sNDA) [...]]]></description>
		<wfw:commentRss>http://annpharmacy.com/blog/anti-acidity/fda-granted-a-priority-review-to-abilifyr-aripiprazole-supplemental-new-drug-application.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Enlarged Indications Of ABILIFY(R) (Aripiprazole) Use</title>
		<link>http://annpharmacy.com/blog/anti-acidity/enlarged-indications-of-abilifyr-aripiprazole-use.html</link>
		<comments>http://annpharmacy.com/blog/anti-acidity/enlarged-indications-of-abilifyr-aripiprazole-use.html#comments</comments>
		<pubDate>Tue, 19 Jan 2010 09:14:42 +0000</pubDate>
		<dc:creator>John Mitchell</dc:creator>
				<category><![CDATA[Anti-Acidity]]></category>
		<category><![CDATA[Anti-Depressants]]></category>
		<category><![CDATA[Abilify]]></category>
		<category><![CDATA[Aripiprazole]]></category>
		<category><![CDATA[Schizophrenia]]></category>

		<guid isPermaLink="false">http://annpharmacy.com/blog/?p=181</guid>
		<description><![CDATA[Taro Iwamoto, Ph.D., Chief Executive Officer,  President and Chief Operating Officer, Otsuka Pharmaceutical Development and  Commercialization, Inc. stated that they are very pleased to receive expanded indications  on the use of Abilify (Aripiprazole) in pediatric patients (aged 10-17) and adolescents.
In fact, The FDA first approved ABILIFY antipsychotic medicine for the treatment of [...]]]></description>
		<wfw:commentRss>http://annpharmacy.com/blog/anti-acidity/enlarged-indications-of-abilifyr-aripiprazole-use.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
